Press Releases
Comstock Inc. to Host Q3 2026 Earnings Call and Business Update
RENO, Nev., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Comstock Inc. (NYSE American: LODE) (“Comstock” and the “Company”) is pleased to announce that the Company's CEO, Corrado De Gasperis, and CFO, Judd Merrill will provide an overview of our third quarter 2026 financial results and current business updates on Wednesday, November 4, 2026, at 4:30pm ET. We invite our investors and all other interested parties to register for the webinar at the link below...
Seagate Simplifies High-Capacity Storage Scaling for AI and Cloud Infrastructure
SINGAPORE--(BUSINESS WIRE)--Seagate expands high-capacity HAMR + SMR storage interoperability with Broadcom, validated at hyperscale by Microsoft Azure.
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Ethan Allen Shareholders Vote the WHITE Proxy Card “FOR” All Five of Doug Bergeron's Director Nominees
PARK CITY, Utah--(BUSINESS WIRE)--Doug Bergeron, a significant shareholder of Ethan Allen Interiors Inc. (“Ethan Allen” or the “Company”) (NYSE: ETD) with beneficial ownership, collectively with his affiliates and associates, of approximately 5.2% of Ethan Allen's outstanding common stock, today announced that leading independent proxy advisory firm Glass, Lewis & Co. (“Glass Lewis”) has recommended that Ethan Allen shareholders vote on the WHITE universal proxy card “FOR” ALL FIVE of his h...
Tutor Perini Announces Conference Call to Discuss Third Quarter 2026 Results
LOS ANGELES--(BUSINESS WIRE)--Tutor Perini Corporation (NYSE: TPC) (the “Company”), a leading civil, building and specialty construction company, announced today that it will host a conference call at 2:00 PM Pacific Time on Wednesday, November 4, 2026, to discuss the Company's third quarter 2026 results. Participants on the call from Tutor Perini will be Gary Smalley, CEO and President; and Ryan Soroka, Executive Vice President and CFO. The Company plans to issue its earnings announcement the...
Sable Offshore Corp. Announces Third Quarter 2026 Earnings Release Date and Conference Call
HOUSTON--(BUSINESS WIRE)--Sable Offshore Corp. Announces Third Quarter 2026 Earnings Release Date and Conference Call.
Blackrock Silver Awards Civil Engineering Works to NewFields for Permit Designs on the Tonopah West Project
Vancouver, British Columbia--(Newsfile Corp. - October 26, 2026) - Blackrock Silver Corp. (TSX: BRC) (OTCQX: BKRRF) (FSE: AHZ0) (the "Company" or "Blackrock") is pleased to announce that its wholly-owned Nevada subsidiary, Blackrock Gold Corp., has entered into a service agreement (the "Service Agreement") with NewFields Mining Design & Technical Services, LLC of Englewood, Colorado ("NewFields") to assist with the design requirements to complete permitting of an exploration decline, test mining and 50,000 tonnes (55,000 tons) bulk-sample extraction on the Company's Tonopah West project ("Tonopah West") located in Nye and Esmeralda Counties, Nevada, USA. NewFields will prepare construction-level designs for Tonopah West's Water Pollution Control Permit and Nevada Reclamation Permit, US Highway 95 tie in and access, and surface facilities needed to place silver and gold laden rock and associated waste rock material at surface as well as site facilities to support technical, construction and contractor needs...
Corxel US and Amanat Acquisition Corp Announce Definitive Business Combination Agreement to Create Publicly Listed Obesity-Focused Biopharmaceutical Company
BERKELEY HEIGHTS, N.J. and WESTFIELD, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Corxel Pharmaceuticals, Inc. (“Corxel US”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for obesity and related cardiometabolic conditions, and Amanat Acquisition Corp (Nasdaq: AMAN) (“Amanat”), a publicly traded special purpose acquisition company, today announced they have entered into a definitive business combination agreement...
GoldCoast Resource Corp. to Present at the Red Cloud Fall Mining Showcase 2026
Toronto, Ontario--(Newsfile Corp. - October 26, 2026) - GoldCoast Resource Corp. (CSE: GCR) (OTC: GCRFF) (FSE: EKW) ("GoldCoast" or the "Company") is pleased to announce that it will participate in the Red Cloud Fall Mining Showcase 2026, taking place October 28-29, 2026 at the Omni King Edward Hotel in Toronto, Ontario. Michael Nikiforuk, Founder, CEO, & Director will present on Wednesday October 28 at 4:00 PM ET in the Sovereign Ballroom and will be available for investor meetings and one-on-ones throughout the event...
Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress
MILLBRAE, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the presentation of updated data for EIK1001 at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain...
Dryden Gold to Present at the Red Cloud Fall Mining Showcase 2026
Vancouver, British Columbia--(Newsfile Corp. - October 26, 2026) - Dryden Gold Corp. (TSXV: DRY) (OTCQX: DRYGF) ("Dryden Gold" or the "Company") is pleased to announce that it will participate in the Red Cloud Fall Mining Showcase 2026, taking place October 28-29, 2026 at the Omni King Edward Hotel in Toronto, Ontario. Trey Wasser, CEO and Director of Dryden Gold, will present on Wednesday, October 28 at 12:00 PM ET in the Vanity Fair room and will be available for investor meetings and one-on-ones throughout the event...
Snowline Gold Appoints Randy Smallwood to Board of Directors
VANCOUVER, British Columbia, Oct. 26, 2026 (GLOBE NEWSWIRE) -- SNOWLINE GOLD CORP. (TSX: SGD) (US OTCQB: SNWGF) (the “Company” or “Snowline”) is pleased to announce the appointment of Randy Smallwood to its Board of Directors (the “Board”) as an Independent Director, effective today.
Zentek Provides Corporate Update on Nasdaq Listing
Guelph, Ontario--(Newsfile Corp. - October 26, 2026) - Zentek Ltd. (TSXV: ZEN) (OTCQX: ZTEKF) ("Zentek" or the "Company") today provides an update on the Nasdaq appeal process it began after The Nasdaq Stock Market LLC ("Nasdaq") issued its delisting determination, as disclosed in the Company's August 28, 2026 news release...
Coloured Ties Announces Non-Brokered Private Placement of up to $1,200,000
Vancouver, British Columbia--(Newsfile Corp. - October 26, 2026) - Coloured Ties Capital Inc. (TSXV: TIE) (OTC Pink: APEOF) (FSE: 97A) ("Coloured Ties" or the "Company") is pleased to announce a non-brokered private placement (the "Offering") of a minimum of 1,293,104 units and a maximum of 2,068,965 units of the Company (each, a "Unit") at a price of $0.58 per Unit, for minimum gross proceeds of $750,000 and maximum gross proceeds of $1,200,000. Each Unit will consist of one common share of the Company (a "Common Share") and one Common Share purchase warrant (a "Warrant")...
Kaplan Fox Urges Investors of FuelCell Energy, Inc. (FCEL) to Seek a Leadership Role Before November 10, 2026
New York, New York--(Newsfile Corp. - October 26, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against FuelCell Energy, Inc. ("FuelCell" or the "Company") (NASDAQ: FCEL) on behalf of investors that purchased or otherwise acquired FuelCell securities between June 24, 2026 and September 1, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in FuelCell and have suffered losses, you may CLICK HERE to contact us...
Red Metal Defines 3-Kilometre Chargeability Trend Along Copper Gold Bearing Vein Structures at Carrizal
Vancouver, British Columbia--(Newsfile Corp. - October 26, 2026) - RED METAL RESOURCES LTD. (CSE: RMES) (OTC: RMESF) (FSE: I660) ("Red Metal" or the "Company") is pleased to report final results from the two-dimensional ("2D") and three-dimensional ("3D") induced polarization ("IP") and resistivity survey completed by Geophysical Studies Chile over its Carrizal Copper-Gold-Cobalt Property ("Carrizal" or the "Property"), near Vallenar in Chile's Atacama Region...
Kaplan Fox Notifies Investors of Endava plc (DAVA) of the Lead Plaintiff Deadline on November 30, 2026
New York, New York--(Newsfile Corp. - October 26, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Endava plc ("Endava" or the "Company") (NYSE: DAVA) on behalf of investors that purchased or otherwise acquired Endava securities between September 4, 2025 and September 21, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Endava and have suffered losses, you may CLICK HERE to contact us...
$CDNL Stock Losses: BFA Law Reminds Cardinal Infrastructure Investors with Losses of the Ongoing Securities Fraud Investigation into Potential Acquisition Misrepresentations
BFA Law Reminds Cardinal Infrastructure Investors with Losses of the Ongoing Securities Fraud Investigation into Potential Acquisition Misrepresentations
$LULU Stock Losses: BFA Law Reminds Lululemon Investors with Losses of the Ongoing Securities Fraud Investigation into Potential Growth Misrepresentations
BFA Law is investigating whether Lululemon committed securities fraud by making false and misleading statements to investors regarding the strength of its growth and overall business health. BFA Law is investigating whether Lululemon committed securities fraud by making false and misleading statements to investors regarding the strength of its growth and overall business health...
$PAG Merger Investigation: BFA Law Reminds Penske Automotive Group Shareholders of Its Ongoing Investigation into the $212.00 per Share Take-Private Merger
NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that it is investigating the going private merger whereby Penske Automotive Group, Inc. (NYSE: PAG) is being taken private by its controlling stockholders, Roger Penske and Mitsui & Co., Ltd. Penske is incorporated in Delaware...
$MDLN Stock Losses: BFA Law Reminds Medline Investors with Losses of the Ongoing Securities Fraud Investigation into Potential Product Quality Misrepresentations
NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Medline Inc. (NASDAQ:MDLN) for potential securities fraud after its significant stock drops. If you invested in Medline securities, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/medline-class-action-lawsuit...
$PSNL Merger Investigation: BFA Law Reminds Personalis Shareholders of Its Ongoing Investigation into the $16.25 per Share Merger Deal
NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that it is investigating the going private merger whereby Personalis, Inc. (NASDAQ: PSNL) is being taken private by Tempus AI, Inc. Personalis is incorporated in Delaware. If you are a current stockholder of Personalis, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/personalis-merger-investigation...
$FUN Stock Losses: BFA Law Reminds Six Flags Investors with Losses of the Ongoing Securities Fraud Investigation into Potential Safety Misrepresentations
NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Six Flags Entertainment Corporation (NYSE:FUN) for potential securities fraud after its significant stock drop. If you invested in Six Flags securities, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/six-flags-class-action-lawsuit...
$ALHC Stock Losses: BFA Law Reminds Alignment Healthcare Investors with Losses of the Ongoing Securities Fraud Investigation into Potential Inflated EBITDA Misrepresentations
BFA Law Reminds Alignment Healthcare Investors with Losses of the Ongoing Securities Fraud Investigation into Potential Inflated EBITDA Misrepresentations
DHI Group, Inc. to Report Third Quarter Financial Results on November 4, 2026
CENTENNIAL, Colo.--(BUSINESS WIRE)--DHI Group, Inc. (NYSE: DHX) ("DHI" or the "Company") today announced that it will report financial results for its third quarter ended September 30, 2026 on Wednesday, November 4, 2026, after the close of the market. Art Zeile, President and Chief Executive Officer, and Greg Schippers, Chief Financial Officer, will host a conference call and webcast at 5:00 pm Eastern Time to discuss the results. A press release with these results will be issued after the clo...
Northern Trust Reappointed by People's Pension
LONDON--(BUSINESS WIRE)--Northern Trust (Nasdaq: NTRS) today announced it has been reappointed by People's Pension to provide fund administration, global custody, securities lending and performance measurement. The agreement extends a relationship that began in 2018 and supports the pension scheme's ongoing investment and operational objectives. People's Pension is one of the United Kingdom's leading workplace pension schemes, serving 7.2 million members and helping businesses across all sector...
BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer
MAINZ, Germany and SHANGHAI, China, October 26, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and DualityBiologics (Suzhou) Co., Ltd. (“DualityBio”, HKEX: 9606.HK) announced today that the DYNASTY-Breast02 global Phase 3 clinical trial (NCT06018337) met its primary endpoint demonstrating a statistically significant, yet modest improvement in progression-free survival (“PFS”) with trastuzumab pamirtecan (BNT323/DB-1303) compared to investigator's choice of chemotherapy in chemotherapy-naïve patients with HR+/HER2-low metastatic breast cancer who have progressed on endocrine therapy. At this interim analysis for the secondary endpoint of overall survival (“OS”), data were not mature...
Volkswagen Group strengthens its strategic semiconductor ecosystem through partnership with NXP
Volkswagen Group and NXP announced agreement on a strategic partnership; NXP's S32K5 MCUs serve as a building block for the Group's future SDV architecture
Conow Launches Award-Winning Atlas 6000 AC in Germany, Advancing AI-Driven Home Energy Management
MUNICH, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Conow, an AI-native digital energy ecosystem brand co-built with global AI cloud platform service provider Tuya Smart (NYSE: TUYA; HKEX: 2391), has launched the Atlas 6000 AC in Germany. The flagship plug-and-play home battery is accompanied by a new concept film showing how Conow AIX uses AI to coordinate home energy generation, storage and consumption...
Regency Silver to Exhibit at the 2026 New Orleans Investment Conference
Vancouver, British Columbia--(Newsfile Corp. - October 26, 2026) - Regency Silver Corp. (TSXV: RSMX) (OTCQB: RSMXF) (FSE: ZJ90) ("Regency Silver" or the "Company") is pleased to announce that it will be exhibiting at the 2026 New Orleans Investment Conference, taking place October 28 to 31, 2026, at the Hilton New Orleans Riverside, 2 Poydras Street, New Orleans, Louisiana. Now in its 50th year, the New Orleans Investment Conference is one of the longest-running and most widely attended resource investment events in North America, bringing together retail and institutional investors, newsletter writers, analysts and mining executives...
Berkshire Hathaway Specialty Insurance Promotes Virginie Pelletier to Head of Executive & Professional Liability in France
BOSTON & PARIS--(BUSINESS WIRE)--Berkshire Hathaway Specialty Insurance Promotes Virginie Pelletier to Head of Executive & Professional Liability in France.
Dover Commences Offers to Purchase for Cash Certain of Its Outstanding Debt Securities
DOWNERS GROVE, Ill., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Dover (NYSE: DOV), a diversified global manufacturer, today announced that it has commenced cash tender offers (collectively, the “Offers”) to purchase the outstanding notes described below, in each case upon the terms and subject to the conditions set forth in the Offer to Purchase dated October 26, 2026 (the “Offer to Purchase”)...
Kaplan Fox Reminds Duolingo, Inc. (DUOL) Investors to Seek a Leadership Role Before Deadline on December 7, 2026
New York, New York--(Newsfile Corp. - October 26, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Duolingo, Inc. ("Duolingo" or the "Company") (NASDAQ: DUOL) on behalf of investors that purchased or otherwise acquired Duolingo Class A common stock between May 2, 2025 and February 26, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Duolingo and have suffered losses, you may CLICK HERE to contact us...
Getty Hits New Copper Zone at Getty South, Drilling 160 Metres Grading 0.32% Copper
Highlights: New copper zone intersected 100-180m northeast of earlier announced intercepts at Getty South, and remains open in multiple directions and to depth Expansion potential to be tested in newly commenced two drill-rig program Vancouver, British Columbia--(Newsfile Corp. - October 26, 2026) - Getty Copper Inc. (TSXV: GTC) (OTCQX: GTCDF) ("Getty" or the "Company") is pleased to report additional assay results for five holes from its spring 2026 drilling at the Getty South target, part of the Company's Getty project in the Highland Valley District of British Columbia. "Today's results show another zone of copper mineralization at Getty South...
HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026
— ORPATHYS plus TAGRISSO reduced the risk of disease progression or death by 44% in the overall population and 55% in the high MET overexpression population in the first-line setting —
Phathom Pharmaceuticals Provides Update on FDA Litigation
FLORHAM PARK, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced the U.S. Food and Drug Administration's (FDA's) establishment of a public docket (Docket No. FDA-2026-N-13038) to solicit comment on legal and regulatory questions regarding certain issues raised by a filer of an abbreviated new drug application (ANDA) referencing VOQUEZNA (vonoprazan) tablets, BDR Pharmaceuticals, International Pvt. Ltd. (BDR), in litigation brought against the FDA following FDA's rejection of the ANDA. The litigation was brought to challenge FDA's June 6, 2025 decision granting Phathom's Citizen Petition, which agreed with Phathom that VOQUEZNA benefits from 10 years of New Chemical Entity (NCE) exclusivity through May 3, 2032. The deadline for comments submitted to the public docket is November 23, 2026...
FTI Consulting Adds Björn Storim to Strengthen Banking and Capital Markets Advisory in Germany
Former CEO of BNY's European Bank brings decades of experience across financial services, regulation and strategic transformation Former CEO of BNY's European Bank brings decades of experience across financial services, regulation and strategic transformation
Honeywell Technologies Launches Forge Plant Cognition with Dangote, Built with NVIDIA AI and Dell Technologies Capabilities
CHARLOTTE, N.C.--(BUSINESS WIRE)--Honeywell Technologies (NASDAQ: HON) has announced the launch of Forge Plant Cognition, an industrial AI platform built with NVIDIA AI and accelerated computing capabilities, and Dell Technologies' AI infrastructure. The platform is designed to help refining, petrochemical and Liquefied Natural Gas (LNG) operators generate greater value from their existing assets and transform plant operations. Launching first at Dangote's petroleum refinery in Lekki, Nigeria –...
PixVerse and OpenAI Collaborate on “Prompt to Production”, a New Learning Initiative for AI-Powered Creative Workflows
SINGAPORE--(BUSINESS WIRE)-- #OpenAI--PixVerse and OpenAI announced Prompt to Production, a collaborative educational initiative designed to help people and teams using AI in their creative workflows. The initiative will show participants how to combine OpenAI frontier models and agentic capabilities with PixVerse's multimodal generation tools. The initiative will begin with two live webinars timed for different regions: one on 28 October 2026 at 12PM GMT+8 for APAC audiences, and one on 29 October 2026...
Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study
BOTHELL, Wash. & PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ESMO--Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung.
Kaplan Fox Announces That Hims & Hers Health, Inc. (HIMS) Investors Have Until November 2, 2026 to Seek Lead Plaintiff Status
New York, New York--(Newsfile Corp. - October 26, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) on behalf of investors that purchased or otherwise acquired Hims & Hers securities between August 4, 2025 and July 29, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Hims & Hers and have suffered losses, you may CLICK HERE to contact us...
Li-FT Announces First Results from Summer Drill Program at the Adina-Galinée Lithium Project, Quebec
VANCOUVER, British Columbia, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Li-FT Power Ltd. (“LIFT” or the “Company”) (TSXV: LIFT) (ASX: LFT) (OTCQX: LIFFF) (Frankfurt: WS0) is pleased to announce assay results from the first 5 of 45 drill holes from the Adina-Galinée Lithium Project (“AGLP”) in Québec, Canada (Figure 1). The 45 holes comprise 39 holes totaling 11,420.5 metres completed as part of LIFT's 2026 summer drilling program, together with 6 previously unreleased historical drill holes from 2024 (1,983 metres), totalling 13,403.5 metres of drill core. Holes ALP-0001 to ALP-0005C from the 2026 drill campaign are presented in this release. The intercepts for drill holes ALP-0001 to ALP-0005C are presented in Table 1 and shown in figures 2, 3 & 4, with a highlight of 56 meters of 1.43 % Li 2 O intersected in drillhole ALP002...
STMicroelectronics introduces first automotive safety combination sensors for mass-market applications
STMicroelectronics introduces first automotive safety combination sensors for mass-market applications Cohesive sensor platform accelerates development of advanced active and passive safety systems First mass-market products launched following the integration of NXP's sensors division earlier this year Geneva, Switzerland, October 26, 2026 – STMicroelectronics (NYSE: STM), a global semiconductor leader serving customers across the spectrum of electronics applications, has announced a set of automotive sensors that enable vehicle brands to extend advanced safety and driver-assistance features across categories from premium to mass-market, broadening access to state-of-the-art protection. Combining multi-axis accelerometers and gyroscopes (angular rate sensors) in a single package, ST's new sensors offer a unified platform for OEMs and Tier-1 suppliers to build active and passive safety systems that meet stringent automotive quality, reliability, and safety requirements...
Norsk Hydro: Reminder - Invitation to Hydro's Investor Day, London
Hydro is pleased to invite investors, analysts, financial media and other stakeholders to its Investor Day on November 25, 2026. The event will be held at 30 Euston Square, London NW1 2FB, with the alternative of joining virtually.
PureTech Presents Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026
BOSTON--(BUSINESS WIRE)--PureTech Presents Phase 1b Results for LYT-200 in Relapsed/Refractory High-Risk Myelodysplastic Syndromes & Acute Myeloid Leukemia (AML) at ESMO 2026.
Kaplan Fox Notifies Investors of Hyliion Holdings Corp. (HYLN) of the Lead Plaintiff Deadline on October 27, 2026
New York, New York--(Newsfile Corp. - October 26, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hyliion Holdings Corp. ("Hyliion Holdings" or the "Company") (NYSE American: HYLN) on behalf of investors that purchased or otherwise acquired Hyliion Holdings securities between May 12, 2026 and June 23, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Hyliion Holdings and have suffered losses, you may CLICK HERE to contact us...
Rokmaster Drills Stockwork and Porphyry at Mystery
Vancouver, British Columbia--(Newsfile Corp. - October 26, 2026) - Rokmaster Resources Corp. (TSXV: RKR) (OTCQB: RKMSF) (FSE: 1RR1) ("Rokmaster" or "the Company") is pleased to provide an update on its maiden drill program at the Mystery Property. Fall drilling operations are now completed on the first of 3 targets on the Mystery Property...
District Reports on Geochemical Results from Nianfors Uranium Property in Sweden
Vancouver, British Columbia--(Newsfile Corp. - October 26, 2026) - District Metals Corp. (TSXV: DMX) (Nasdaq First North: DMXSE SDB) (OTCQX: DMXCF) (FSE: DFPP); ("District" or the "Company") is pleased to announce the results of its summer 2026 reconnaissance field program at the 100% owned Nianfors Property located in Gävleborgs County, Sweden. The field program was designed to follow up on prominent uraniferous radiometric anomalies identified by the Company's property-wide Unmanned Aerial Vehicle ("UAV") radiometric and magnetic survey completed in 2025 and to advance priority areas toward drill targeting...
Helium Added to U.S. Department of Energy Critical Material List
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR TO BE TRANSMITTED, DISTRIBUTED TO, OR SENT BY, ANY NATIONAL OR RESIDENT OR CITIZEN OF ANY SUCH COUNTRIES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION MAY CONTRAVENE LOCAL SECURITIES LAWS OR REGULATIONS...
Wolters Kluwer selected by IFFCO Tokio General Insurance to support Ind AS 117 and Ind AS 116 compliance with CCH® Tagetik
MUMBAI, India--(BUSINESS WIRE)--Wolters Kluwer, a global leader in professional information, software solutions and services, today announced that IFFCO Tokio General Insurance Company Limited, a leading general insurance provider in India, has selected CCH Tagetik to support Ind AS 117 (IFRS 17) compliance disclosure reporting requirements, and broader finance transformation initiatives. This initiative comes as India's insurance sector prepares for the adoption of Ind AS 117, the country's i...
CSQR Investors with $100,000 in Losses Have Opportunity to Join Csquare, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $CSQR--CSQR Investors with $100,000 in Losses Have Opportunity to Join Csquare, Inc. Fraud Investigation with SBS Law.
Nasdaq Strengthens Asia-Pacific Leadership Team
Andrew Murray joins as Senior Vice President to deepen Nasdaq's Financial Technology client partnerships across Asia-Pacific as the region enters a defining era of market evolution
TTMI Investors with $100,000 in Losses Have Opportunity to Join TTM Technologies, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $TTMI--TTMI Investors with $100,000 in Losses Have Opportunity to Join TTM Technologies, Inc. Fraud Investigation with SBS Law.
HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine
— ORPATHYS plus TAGRISSO reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO —
OpenWorld Confirms Dual Listing on Figure OPEN on Track for Q4 2026 Following Stockholder Approval of Blockchain Common Stock
OpenWorld (“OPNW”) stockholders will be able to hold and trade a blockchain version of their existing shares on Figure OPEN alongside the Company's Nasdaq listing with no shareholder dilution OpenWorld (“OPNW”) stockholders will be able to hold and trade a blockchain version of their existing shares on Figure OPEN alongside the Company's Nasdaq listing with no shareholder dilution
Faraday Future Announces YT Jia's Investor Weekly Report Rescheduled to October 26; FFR to Hold Listing Ceremony and Investor Day on October 26
LOS ANGELES--(BUSINESS WIRE)--Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future,” “FF,” or the “Company”), a California-based global Embodied AI (“EAI”) ecosystem company, today announced that this week's Investor Weekly Report from FF Founder and Global CEO YT Jia has been rescheduled to October 26. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) will hold its Listing Ceremony and Investor Day on October 26, 2026. During the event, FFR management will outline the company's...
KALDVÍK AS (KLDVK): Extension of waiver period
Frøya, 25 October 2026: Reference is made to the Company's announcement of 1 October 2026 regarding the waiver agreement with its lenders. As 25 October 2026 falls on a non-banking day, the lenders have agreed to extend the waiver period until and including Monday, 26 October 2026. The Company remains in dialogue with its lenders and relevant stakeholders regarding its financing position and will provide a further update when appropriate...
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026
MENLO PARK, Calif., Oct. 25, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppurativa (HS), today announced it will report Week 16 data for ORKA-001 from the ongoing EVERLAST-B Phase 2b trial in moderate-to-severe plaque psoriasis on Monday, October 26, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results...
Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that its partner Akeso Inc. announced positive results from the Phase III HARMONi-GI1 study evaluating the novel, potential first-in-class investigational bispecific antibody ivonescimab plus chemotherapy compared with durvalumab plus chemotherapy as a first-line treatment for patients with advanced biliary tract cancer (BTC). These data are featured in today's Presidential Symposium II at the European Society for Medic...
TAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the SAFFRON Phase III trial showed TAGRISSO (osimertinib) plus savolitinib demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival (PFS) and overall survival (OS) versus doublet platinum-based chemotherapy in patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). Patients in the trial had tumors with high levels of MET overexpression or amplification and had progressed on prior treatment with TAGRISSO...
Genentech's Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Divarasib demonstrated best-in-class efficacy in Phase III trial, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer.
Roche's divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer
Basel, 25 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today pivotal results from the phase III Krascendo 1 study, which demonstrated the superior efficacy of investigational divarasib, a next-generation KRAS G12C inhibitor, compared with current standard of care KRAS G12C inhibitors in people with previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC)...
Subcutaneous RYBREVANT®▼ (amivantamab) demonstrates 77% overall response rate in first-line treatment of patients with certain types of advanced head and neck cancer
BEERSE, BELGIUM, Oct. 25, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new results from Cohort 5 of the Phase 1b/2 OrigAMI-4 study with first-line subcutaneous RYBREVANT▼ (amivantamab) plus a PD-1 inhibitor and fixed-duration carboplatin chemotherapy in patients with advanced recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) other than human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC).1 These findings support the ongoing pivotal Phase 3 OrigAMI-5 study and further expand the clinical development programme for subcutaneous amivantamab for patients with head and neck cancer...
ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026
NEWTOWN SQUARE, Pa., Oct. 25, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced initial encouraging Phase 1 results for ARR-217, (MRG007), a cadherin-17 (CDH17)-targeting antibody-drug conjugate (ADC) developed in partnership with Lepu Biopharma Co., Ltd., in patients with gastrointestinal malignancies. The findings were presented as part of an oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress 2026...
Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM)
Pre-specified and Statistically Powered Key Endpoints Included Progression-free Survival (PFS) and Overall Survival (OS). Although Primary Endpoint of PFS Was Not Met, The Key Secondary Endpoint of OS Was Improved With VAZKEPA/VASCEPA
Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
Media Release COPENHAGEN, Denmark; October 25, 2026 Petosemtamab demonstrates encouraging objective response rates (ORRs), with promising depth and durability of response, in first- and second-line metastatic colorectal cancer (mCRC) Data reinforces the ongoing global Phase 3 trials of petosemtamab in mCRC, which are actively enrolling patients Genmab A/S (Nasdaq: GMAB) today announced updated follow-up analyses from a Phase 2 trial evaluating petosemtamab, an investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), in combination with FOLFOX or FOLFIRI in patients with metastatic colorectal cancer (mCRC). At a median follow-up of 5.9 months in the first-line (1L) setting and 7.1 months in the second-line (2L) setting, confirmed and unconfirmed objective response rates (ORRs) were 75% and 67%, respectively, with an ORR of 81% observed among 1L patients with left-sided tumors...
NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development
Nearly 18 months of median follow-up, selection of the 8 mg/kg dose and FDA engagement strengthen the foundation for registrational development in first-line metastatic gastroesophageal adenocarcinoma Nearly 18 months of median follow-up, selection of the 8 mg/kg dose and FDA engagement strengthen the foundation for registrational development in first-line metastatic gastroesophageal adenocarcinoma
Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced early Phase 2 results from the mismatch repair-deficient (dMMR) colon cancer cohort of NEOASIS, an investigator-initiated pan-tumor study sponsored by the Netherlands Cancer Institute (NKI). NEOASIS is evaluating botensilimab (BOT), Agenus' multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus' anti-PD-1 antibody, given before surgery...
Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)
Longer-term data reflecting nearly 4 years of follow-up show a further reduction in the risk of death from 14% to 37% for those initially treated with Libtayo, despite an 88% crossover from the placebo arm upon recurrence
Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced updated results from the Phase 1 study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in patients with advanced clear cell renal cell carcinoma (ccRCC). The results were presented by Sumanta Pal, M.D., FASCO, professor and vice chair of academic affairs at City of Hope Comp...
BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
MAINZ, Germany, and PRINCETON, USA, October 25, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb Company (NYSE: BMY, “BMS”) today announced first data from the global Phase 2 ROSETTA Lung-107 clinical trial (NCT06841055) evaluating pumitamig, an investigational PD-L1xVEGF-A bispecific immunomodulator (BNT327/BMS986545), in combination with docetaxel in patients with metastatic non-small cell lung cancer (“NSCLC”) whose disease progressed on or after first-line immunotherapy plus chemotherapy...
Prospera Energy Announces Service Rig Update as Luseland Workovers Come Online at 3.3x Prior Rates
Calgary, Alberta--(Newsfile Corp. - October 24, 2026) - Prospera Energy Inc. (TSXV: PEI) (OTC Pink: GXRFF) ("Prospera", "PEI", the "Corporation", or the "Company") announces an update on its fall service rig program. All five Luseland wells worked over between September 21st and October 10th, 2026, have returned to production and have averaged a combined 53.5 bbl/d of oil since first oil, up from 16.0 bbl/d before the workovers...
Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026
Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, consistent with Phase 1b data; additional data from the PrisMN Phase 2 study anticipated in 2027
Teck Provides Update on Highland Valley Copper Operations
VANCOUVER, British Columbia, Oct. 24, 2026 (GLOBE NEWSWIRE) -- Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) (“Teck”) announced today that strike action by United Steelworkers (USW) Local 7619 has commenced at Teck's Highland Valley Copper (HVC) Operations in B.C.
CCC Investors Have Opportunity to Join CCC Intelligent Solutions Holdings Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $CCC--CCC Investors Have Opportunity to Join CCC Intelligent Solutions Holdings Inc. Fraud Investigation with SBS Law.
Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed results across serotypes from a Phase 2 study (NCT06524414) for its investigational 25-valent pneumococcal conjugate vaccine candidate, PF-07872412 (25vPnC), in infants. In the study, a four-dose series of 25vPnC elicited robust immune responses against all 25 serotypes and showed safety and tolerability comparable to four doses of PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine). These findings were shared today...
IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
Nearly 80% of Patients Were Alive at One Year Versus 53% with IMFINZI Alone and Progression-Free Survival More Than Tripled Late-Breaking Phase 3 DeLLphi-305 Results Presented in ESMO Presidential Symposium and Simultaneously Published in The New England Journal of Medicine Longer DeLLphi-303 Follow-Up Data Showed Median Overall Survival Exceeded 37 Months in First-Line Maintenance with IMDELLTRA and Either IMFINZI or TECENTRIQ THOUSAND OAKS, Calif., Oct. 24, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced landmark interim Phase 3 results showing that IMDELLTRA (tarlatamab-dlle) in combination with AstraZeneca's IMFINZI (durvalumab) reduced the risk of death by 58% as a first-line maintenance treatment for extensive stage small cell lung cancer (ES-SCLC) (hazard ratio [HR]: 0.42; 95% confidence interval [CI]: 0.32, 0.54; P
Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the VOLGA Phase III trial showed perioperative treatment with AstraZeneca's IMFINZI (durvalumab) in combination with neoadjuvant enfortumab vedotin (EV) demonstrated statistically significant and clinically meaningful improvements in the primary endpoint of event-free survival (EFS) and key secondary endpoint of overall survival (OS) in patients with muscle-invasive bladder cancer (MIBC) versus standard of care. Patients were ineligible...
Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk localised or locally advanced prostate cancer
BEERSE, BELGIUM , Oct. 24, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use of apalutamide plus hormone therapy (androgen deprivation therapy), given for six months before and after surgery, with radical prostatectomy alone in patients with high-risk localised or locally advanced prostate cancer.1 The apalutamide plus hormone therapy regimen reduced the risk of disease recurrence or death by 62% compared with surgery alone.1 The regimen also showed a nominal improvement in metastasis-free survival (MFS), with a 51% lower risk of metastasis or death.1 Patients receiving perioperative treatment also experienced longer time to subsequent therapy compared with surgery alone.1
Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer
New substudy results showed a 51% lower estimated risk of metastasis or death over time with perioperative apalutamide plus ADT compared with immediate surgery Twice as many patients remained free from subsequent treatment at three years with perioperative apalutamide plus ADT compared with surgery alone Results evaluated outcomes versus surgery alone, building on the primary results presented at ASCO 2026 NEW BRUNSWICK, N.J., Oct. 24, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use of apalutamide plus androgen deprivation therapy (ADT), given for six months before and after surgery, with radical prostatectomy alone in patients with high-risk localized or locally advanced prostate cancer...
Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors
CAMBRIDGE, Mass., Oct. 24, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced updated safety and efficacy data for zolucatetide, the first and only direct inhibitor of the β-catenin:TCF interaction, in patients with desmoid tumors. The data were presented today in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27, 2026, in Madrid, Spain. The updated results, based on a June 22, 2026, data cutoff, include data from both the dose escalation and dose optimization portions of the ongoing Phase 1/2 trial and reinforce the strong efficacy and favorable safety and tolerability profile observed with zolucatetide. Among response-evaluable patients who began treatment at a starting dose of ≥450 mg, zolucatetide demonstrated an objective response rate (ORR) of 72.2% (13/18) in a 32-week landmark analysis. A disease control rate (DCR) of 100% was observed across all 46 response-evaluable patients who received a starting dose of ≥450 mg, with no disease progression. Data from a three-arm randomized dose optimization trial supported selection of a 450 mg weekly induction regimen administered for four cycles, followed by 300 mg every two weeks for long-term maintenance. Following productive end-of-Phase 2 discussions, Parabilis has reached alignment with the U.S. Food and Drug Administration (FDA) on the selected dose and regimen, on the use of a placebo-controlled study design, and on progression-free survival (PFS) as the primary endpoint for registrational development. Parabilis plans to initiate the randomized, double-blind PEDESTAL Phase 3 trial (Phase 3 Evaluation of DESmoid Tumor Activity with zoLucatetide) in the first half of 2027, with topline results anticipated in 2029. “Desmoid tumors are chronic and life-altering for patients, often affecting people at a young age, and patients need treatments that can deliver rapid, deep and durable tumor responses with a tolerability profile suited for long-term treatment,” said Mathai Mammen, M.D., Ph.D., Chairman, CEO and President of Parabilis Medicines. “We designed zolucatetide to directly inhibit β-catenin:TCF, a historically undruggable target at the heart of the biology driving these tumors. The depth and consistency of responses we are seeing, together with the favorable safety and tolerability profile observed to date, reinforce our conviction that zolucatetide has the potential to deliver a truly differentiated medicine and meaningfully expand the number of patients who can benefit from treatment. We are very pleased with the clarity of the FDA's feedback on our registrational development strategy, and with our Phase 3 regimen selected, we are moving with urgency to bring this medicine to patients.” Updated Phase 1/2 Results As of the June 22, 2026, data cutoff, 76 patients with desmoid tumors had been enrolled and treated across all dose levels in the dose escalation and dose optimization portions of the trial. Median age was 37 years (range 19–80), and 69.7% of patients were female. The population included both patients who had previously been treated with and failed gamma-secretase inhibitors (GSIs) and patients naive to GSIs...
Semtech Brings 5G Network Slicing, FIPS 140-3 to IACP 2026
CAMARILLO, Calif.--(BUSINESS WIRE)--Semtech Corporation (Nasdaq: SMTC), a leading provider of high-performance semiconductors powering AI data center networking and intelligent, connected Internet of Things (“IoT”) devices worldwide, is adding new resilient communications building blocks to its AirLink 5G Networking Solutions. Semtech will demonstrate the new capabilities in booth #2964 at the International Association of Chiefs of Police (IACP) conference in Orlando, Fla. First responders rel...
ESMO 2026: NUBEQA® (darolutamide) Plus ADT and Radiation Therapy Reduces Risk of Metastasis or Death by 58% in Prostate Cancer Patients at High Risk of Recurrence
WHIPPANY, N.J.--(BUSINESS WIRE)--ESMO 2026: NUBEQA plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence.
BioInvent's BI-1808 and KEYTRUDA(R) Induce Durable Responses in Heavily Pretreated Platinum-Resistant Ovarian Cancer
BioInvent International (STO:BINV) - Updated efficacy data in 34 evaluable patients with a chemotherapy-free regimen; randomized Part C will add BI-1808 to the new standard of care.
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
COPENHAGEN, Denmark & WILMINGTON, Del.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Incyte (Nasdaq: INCY) today announced a clinical trial collaboration to evaluate petosemtamab, Genmab's investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), in combination with INCB161734, Incyte's investigational, potent and selective KRAS G12D inhibitor, and standard-of-care chemotherapy as a fi...
NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma
In 24 heavily pre-treated patients with advanced primary cutaneous melanoma whose cancer had progressed after multiple prior lines of therapy including anti-PD-1 therapy, data continue to show an acceptable safety profile and early signals of efficacy 41.7% (10/24) overall response rate (ORR) per RECIST 1.1, including 4 complete responses 75% (18/24) disease control rate (DCR) 17.8 months median Overall Survival Exploratory analysis in a subset of patients (n=8) identified IL-1β, a cytokine linked to treatment-induced anti-tumor immunity, as the most increased plasma cytokine after treatment Investigators concluded that these preliminary findings warrant further evaluation in randomized clinical trials for patients with primary cutaneous melanoma naïve or refractory to anti-PD-1 Data presented at the 2026 Congress of the European Society for Medical Oncology PARIS and CAMBRIDGE, Mass., Oct. 24, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced updated results from patients with anti-PD-1-resistant advanced primary cutaneous melanoma treated in the ongoing Phase 1 Study 1100...
Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
WILMINGTON, Del. & COPENHAGEN, Denmark--(BUSINESS WIRE)---- $INCY--Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer.
Investor Notification: Penske Automotive Group ($PAG) Investors Are Reminded to Contact BFA Law About the Ongoing Investigation into $212.00 per Share Take-Private Merger Deal
BFA Law is investigating the announced $212.00 per share merger in which Roger Penske and Mistui & Co., Ltd. are set to acquire Penske Automotive Group, Inc.; current shareholders are notified to contact the firm.
Investor Notification: Six Flags ($FUN) Investors Are Reminded to Contact BFA Law About the Ongoing Securities Fraud Investigation to Recover Losses
BFA Law is investigating whether Six Flags Entertainment Corporation committed securities fraud relating to statements about its focus on safety, maintenance, and ride reliability. New York, New York--(Newsfile Corp. - October 24, 2026) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Six Flags Entertainment Corporation (NYSE: FUN) for potential securities fraud after its significant stock drop...
Investor Notification: Personalis, Inc. ($PSNL) Investors Are Reminded to Contact BFA Law About the Ongoing Investigation into $16.25 per Share Merger Deal
BFA Law is investigating the announced $16.25 per share merger in which Tempus AI, Inc., a commercial associate of Personalis, is set to acquire all outstanding Personalis stock; current stockholders are notified to contact the firm. New York, New York--(Newsfile Corp. - October 24, 2026) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that it is investigating the going private merger whereby Personalis, Inc. (NASDAQ: PSNL) is being taken private by Tempus AI, Inc. Personalis is incorporated in Delaware...
Investor Notification: CCC Intelligent Solutions Inc. ($CCC) Investors Are Reminded to Contact BFA Law About the Ongoing Securities Fraud Investigation to Recover Losses
BFA Law is investigating the announced $7.75 per share merger in which a coalition led by GTRC LLC and including Elliott Investment Management L.P. is set to acquire CCC Intelligent Solutions, Inc.; current shareholders are notified to contact the firm.
Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026
BOSTON, Oct. 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the publication of results from the positive Phase 2/3 COMPANION-002 study of tovecimig in combination with paclitaxel in patients with previously treated, advanced biliary tract cancer (BTC) in the Journal of Clinical Oncology (JCO). The results are also being presented today by Nilofer S. Azad, M.D., Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain. The full publication is available via open access at https://ascopubs.org/toc/jco/0/ja...
Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026
Median PFS was 21.5 months with the gedatolisib triplet and 11.5 months with the gedatolisib doublet versus 9.1 months with alpelisib + fulvestrant in patients who had no liver metastases
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne's solid tumor franchise. Mark Lanasa, M.D., Ph...
Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026
Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with similar activity observed across FR α expression levels Clinical activity with Sofe-M was maintained even in patients with prior PARP inhibitor exposure, patients who typically experience poor outcomes with platinum-based chemotherapy Sofe-M is currently being studied in both platinum-sensitive and platinum-resistant ovarian cancer in multiple Phase 3 studies as part of the FRAmework-01 master protocol INDIANAPOLIS, Oct. 24, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its investigational folate receptor alpha (FRα) antibody-drug conjugate (ADC) sofetabart mipitecan (Sofe-M) plus bevacizumab achieved a confirmed objective response rate (cORR) of 79% and a disease control rate (DCR) of 100% in patients with platinum-sensitive ovarian cancer (PSOC). A cORR of 79% or higher was seen in both poly (ADP-ribose) polymerase inhibitor (PARPi)-treated and PARPi-naïve patients...
Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting
Houston, Texas and Tuebingen, Germany, October 24, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced updated clinical trial data from its ongoing Phase 1b study with IMA402 PRAME bispecific and its Phase 1 study with IMA203CD8 PRAME cell therapy...